NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/11/2024
Voltar para busca
Dado oficial do USPTO
LINCTOBC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
LINCTOBC
ST13
US500000079332438Classe
9, 42, 44
Pedido
79332438
Registro
7220365
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
22/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 42, 44
Data de depósito
17/11/2021
Data de registro
21/11/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/11/2023
Última transação
21/11/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
YOO, JEANE
Unidade examinadora
N20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Representantes
Cathleen E. Stadecker Downs Rachlin Martin PLLC
Classificação técnica
Classes Nice
Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Scientific and research apparatus and instruments in the field of healthscientific apparatus and instruments for measuring relative DNARNA and protein and parts and fittings thereforprisms for scientific and medical research purposes; Recorded software for diagnosing the risk of developing breast cancer; Downloadable computer application software for mobile phones and handheld computers for diagnosing the risk of developing breast cancer; Downloadable computer software for diagnosing the risk of developing breast cancer and downloadable computer application software for mobile devices for diagnosing the risk of developing breast cancer; Downloadable computer software platforms for diagnosing the risk of developing breast cancer and downloadable mobile application software for diagnosing the risk of developing breast cancer; All of the aforesaid goods dedicated to the diagnosisprognosis and management of breast cancer therapy
Classe 42
Scientific research services for medical purposes in the field of breast cancer therapy; Medical research; Designdevelopmentmaintenance and updating of computer software; Development of computer platforms; Computer system design; Computer programming; Electronic data storage; Computer software consultancy; Software as a service (SaaS) services featuring software for diagnosing the risk of developing breast cancer; Platform as a service (PaaS) featuring computer software platforms for diagnosing the risk of developing breast cancer; All of the aforesaid goods dedicated to the diagnosisprognosis and management of breast cancer therapy
Classe 44
Health servicesoncologic health care; Medical services; Therapeutic servicesradiotherapeutic agent therapyimmunotherapeutic agent therapychemotherapeutic agent therapy services and surgery; Medical assistance; Medical clinic services and medical analysis services provided by medical laboratories for diagnostic and therapeutic treatment purposes; Advice regarding health; Telemedicine services; All of the aforesaid goods dedicated to the diagnosisprognosis and management of breast cancer therapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/03/2024
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
22/02/2024
XXCR
GENERIC MADRID TRANSACTION CREATED
22/02/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
21/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/09/2023
PUBO
PUBLISHED FOR OPPOSITION
05/09/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/09/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
16/08/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
16/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
25/07/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/07/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/06/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
26/06/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
19/04/2023
GNFR
FINAL REFUSAL E-MAILED
19/04/2023
CNFR
FINAL REFUSAL WRITTEN
19/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/03/2023
RFNT
REFUSAL PROCESSED BY IB
08/11/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/10/2022
RFRR
REFUSAL PROCESSED BY MPU
20/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/08/2022
CNRT
NON-FINAL ACTION WRITTEN
26/08/2022
DOCK
ASSIGNED TO EXAMINER
22/08/2022
MAFR
APPLICATION FILING RECEIPT MAILED
08/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/02/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LINCTOBC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.